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Abstract. Several lines of evidence suggest disturbances of the hypothalamic- 
pituitary-adrenal (HPA) system in Alzheimer’s disease (AD). In an exploration of 
the potential role of the glucocorticoid receptor (GR) in AD, GR density and 
affinity were assessed on mononuclear leukocytes of 12 AD patients and 12 healthy 
controls. GR binding characteristics did not differ between patients and controls or 
between patients subdivided according to diagnosis or associated clinical features. 
These data suggest hat the abnormalities of the HPA system in AD are not related 
to a GR deficiency. 
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Abnormalities of the hypothalamic-pituitary-adrenal (HPA) system linked to Alzhei- 
mer’s disease (AD) include insufficient cortisol suppression following dexamethasone 
administration (Raskind et al., 1982; Spar and Gerner, 1982; Davis et al., 1986) and 
hypersecretion of cortisol (Davis et al., 1986). A recent study noted elevated 36-hour 
cortisol levels in AD patients that tended to normalize during the second sampling 
night following adaptation to the experimental procedure, while 36-hour levels of 
adrenocorticotropic hormone (ACTH) and corticotropin releasing hormone (CRH)- 
stimulated ACTH values did not differ from those of nondemented controls (Heuser 
et al., 1989). 
Although several lines of evidence suggest multiple disturbances of neurotransmit- 
ter function in the central nervous system (Hardy et al., 1985; Sofic et al., 1988) as 
responsible for the hypercortisolemia observed in AD (Davis et al., 1986) the exact 
origin of the HPA system disturbance is still to be resolved. As glucocorticoids exert 
most of their effects via specific intracellular receptors, which are known to decrease 
during aging independent of age-related cell loss (Sapolsky et al., 1986) and which may 
be down-regulated by glucocorticoids (Schlechte et al., 1982) the present study was 
designed to explore the potential role of the glucocorticoid receptor (CR) in the 
disturbance of the HPA system in AD in relation to age, duration, and severity of 
illness. 
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Methods 
Subjects. Twelve medication-free patients (5 men and 7 women) meeting DSM-III-R criteria 
(American Psychiatric Association, 1987) for primary degenerative dementia of the Alzheimer 
type (DAT) and NINCDS-ADRDA criteria (McKhann et al., 1984) for probable AD were 
studied at least 7 days following hospital admission. Their mean age and their mean body weight 
were 65.1 f 9.7 (* SD) years and 72.5 f 10.2 (* SD) kg, respectively. 
Patients were evaluated by physical examination, routine laboratory screening, and various 
imaging techniques, including event related potentials, brain electrical activity mapping 
(BEAM), computed tomography (CT) or magnetic resonance imaging (MRI), and single 
photon emission computed tomography (SPECT) with HMPAO (hexamethylpropylenamine- 
oxime), all of which showed results compatible with DAT-e.g., decreased cerebral blood flow, 
atrophy, and electroencephalographic (EEG) slowing, especially in the parietotemporal brain 
regions. The mean duration of illness was 3.7 f 1.6 (* SD) years. 
Six patients suffered from presenile and six from senile DAT. Severity of dementia was 
assessed by Folstein’s Mini-Mental State (MMS) examination (Folstein et al., 1975) and the 
Brief Cognitive Rating Scale (BCRS; Reisberg et al., 1983) as rating scales, and the Short 
Syndrome Test (SKT, Erzigkeit, 1986) as a psychometric test. The mean (* SD) scores were 19.3 
f 5.7 for the MMS, 35.6 * 9.4 for the BCRS, and 19.1 f 3.7 for the SKT. Six of the patients 
additionally met DSM-III-R criteria for DAT with depression. 
Twelve healthy subjects (3 men and 9 women) served as controls. Their mean (* SD) age was 
62.5 f 12.6 years, and their mean (* SD) body weight was 67.6 + 8.7 kg. 
For determination of GR binding characteristics and hormone levels, 50 ml of blood were 
collected at 1600h as previously noted (Rupprecht et al., in press). The controls were free of any 
psychiatric history and had not taken any medication for at least 4 weeks. All female subjects 
were postmenopausal at the time of the study. 
GR Assay. GR pharmacological characteristics were determined as described in detail else- 
where (Rupprecht et al., in press). In brief, a mononuclear cell fraction was prepared by sodium 
metrizoate-Ficoll density gradient centrifugation (Boyum, 1968). Cells were washed two times 
in PBS for 10 min, incubated for 60 min at 37 “C, and then washed again to allow sufficient 
dissociation of endogenous hormone. The final concentration of cells was determined using a 
Coulter Counter (Model S5, Coulter Electronics Ltd, England). Viability of cells exceeded 95%, 
as judged from their ability to exclude trypan blue. Contamination by erythrocytes was < lo%, 
and contamination by granulocytes and monocytes was < 8%. The cells were incubated with 
increasing amounts of ,H-dexamethasone with 10 pM unlabeled dexamethasone added to 
determine nonspecific binding. After a 90-min incubation, bound ligand was separated from 
free ligand by rapid filtration through Scatron filters with a Titertek cell harvester. The filters 
were monitored for tritium in a Beckman LS 1801 counter at about 54Ycefficiency. All samples 
were assayed in triplicate with a variation within a single experiment of < 7%. 
Hormone Assays. ACTH was measured by a newly developed IRMA supplied by the Nichols 
Institute (San Juan Capistrano, CA), which does not require extraction procedures (Raff and 
Findling, 1989). The lower detection limit was 1.5 pmol/l, and the intra-assay and interassay 
coefficients of variation were 3% and 6.8%, respectively. 
Cortisol was measured by a direct radioimmunoassay (Stalla et al., 1981). The lower detec- 
tion limit was 25 nmol/l, and the intra-assay and interassay coefficients of variation were 5% 
and 9%, respectively. 
Data Analysis. Preliminary estimates of binding parameters from saturation experiments 
were provided by the EBDA program (McPershon, 1983). Final estimates of binding parame- 
ters were determined with a computerized nonlinear, least-square regression analysis (Munson 
and Rodbard, 1980). The results are expressed as the mean * SD. Data were analyzed by 
one-way analysis of variance (ANOVA) followed by post hoc comparison with Student’s t test 
and Pearson’s product-moment correlation. All significance levels are two-tailed. 
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Results 
No significant difference was found for ACTH or cortisol levels (Table 1). GR sites per 
cell (F = 1.1, df = 23, p = 0.2) and GR affinity (F= 0.3, df = 23,~ = 0.14) did not differ 
between the groups (Table 2). Age failed to correlate with GR sites per cell or GR 
affinity in either patients or controls or in both groups combined (Table 3). 
Table 1. ACTH and cortisol levels of DAT patients and 
controls 
ACTH (pmol/l) Cortisol (nmol/l) 
Subjects Mean SD Mean SD 
Patients (n = 12) 3.6 3.0 262.1 93.8 
Controls (n = 12) 5.1 6.9 229.7 79.3 
Note. DAT = dementia of the Alzheimertype. ACTH =adrenocorticotropic hormone. 
GR density and GR affinity did not correlate with duration of illness, severity of 
DAT measured by MMS, BCRS, or SKT scores, or levels of ACTH or cortisol. 
Table 2. GR sites/cell and Kd levels of DAT patients and 
controls 
Subjects 
Patients (n = 12) 
Controls in = 12) 
GR sites/cell Kd (nM) 
Mean SD Mean SD 
4065 1249 14.3 3.2 
3270 1300 11.1 6.1 
Note. GR = glucocorticoid receptor. DAT = dementia of the Alzheimer type. 
Moreover, no differences in GR binding characteristics were observed between men 
and women, senile and presenile DAT patients, or depressed and nondepressed DAT 
patients. 
Table 3. Age: Correlations with GR sites/cell and Kd 
GR sites Kd 
Subjects r P r P 
Patients 0.02 NS 0.36 NS 
Controls 0.03 NS -0.03 NS 
Both groups 0.06 NS 0.11 NS 
Note. GR = glucocorticoid receptor. 
Discussion 
This study did not reveal disturbances of GR pharmacological parameters on mono- 
nuclear leukocytes in AD. In addition, neither GR density nor GR affinity were 
related to duration of illness, severity of DAT, or depressed/nondepressed subtype. 
These findings support the hypothesis that the mild hypercortisolemia partly observed 
in DAT patients (Davis et al., 1986) is not capable of down-regulating the CR. 
Moreover, hypercortisolemia and insufficient suppressibility of cortisol by dexa- 
methasone are not likely a consequence of a specific GR defect occurring in AD but 
may arise from an impaired ability of DAT patients to adapt to stressful events--e.g., 
hospital admission or a neuroendocrine test protocol (Heuser et al., 1989). In this 
study, ACTH and cortisol levels of the patients did not differ from those of controls. 
However, it should be noted that we studied GR binding characteristics only under 
baseline conditions, which may not detect a potential slight deficiency of the CR 
autoregulation capacity being highly sensitive also in humans (Rupprecht et al., in 
press). Furthermore, there may be differences in GR regulation between distinct brain 
regions and peripheral blood cells. Type I and Type II corticosteroid-receptors have 
been shown to underlie a more sensitive regulatory effect of corticosteroids in the 
hippocampus in comparison to other brain regions (McEwen et al., 1987). Moreover, 
an exaggerated cortisol reponse to a glucose tolerance test has recently been reported 
to be related to hippocampal atrophy in DAT patients (de Leon et al., 1988). Thus, the 
regulation of both subtypes of corticosteroid receptors in the brain with their behav- 
ioral and endocrinological implications is highly complex (De Kloet et al., 1987), and 
it would be premature to attempt to generalize from peripheral hormonal levels or 
receptor pharmacology to putative brain function. 
In addition, GR autoregulation has recently been shown to be impaired in aged rats, 
possibly due to a deficit in GR biosynthesis (Eldridge et al., 1989). A decrease of CR 
autoregulatory plasticity comprising GR density with increasing age might therefore 
play a role in the changes in the activity of the HPA system observed during aging 
(Landfield et al., 1978). 
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